- •The Sclera
- •Preface
- •Contents
- •1.1 Introduction
- •1.2 Development of the Sclera
- •1.2.1.1 First Week
- •1.2.1.2 Second Week
- •1.2.1.3 Third Week
- •1.2.1.4 Fourth Week
- •1.2.1.5 Fifth Week
- •1.2.1.6 Sixth Week
- •1.2.1.7 Seventh Week
- •1.2.1.8 Ninth Week
- •1.2.1.9 Tenth Week
- •1.2.1.10 Thirteenth Week
- •1.2.1.11 Sixteenth Week
- •1.2.1.12 Twenty-Fourth Week
- •1.2.2.1 Collagens
- •1.2.2.2 Proteoglycans
- •1.2.2.3 Glycoproteins
- •1.3 Anatomy
- •1.3.1 Gross and Microscopic Anatomy
- •1.3.1.1 Scleral Foramina
- •Anterior Scleral Foramen
- •Posterior Scleral Foramen
- •1.3.1.2 Layers of the Sclera
- •Episclera
- •Scleral Stroma
- •Lamina Fusca
- •1.3.1.3 Blood Supply and Emissary Canals
- •Vascular Distribution
- •Circulatory Dynamics
- •1.3.1.4 Nerve Supply
- •1.3.2 Ultramicroscopic Anatomy
- •1.3.2.1 Sclera
- •1.3.2.2 Vessels
- •1.4 Biochemistry
- •1.5 Immunohistochemistry
- •1.6 Biomechanics
- •1.7 Molecular Structure
- •1.7.1 Collagen
- •1.7.2 Elastin
- •1.7.3 Proteoglycans
- •1.7.4 Glycoproteins
- •1.7.6 Fibroblast Growth Regulation
- •1.8 Summary
- •References
- •2.1 General Immune Response Considerations
- •2.1.1 Components of the Adaptive Immune Response
- •2.1.1.1 Lymphocytes
- •T Lymphocytes
- •B Lymphocytes
- •Third-Population Lymphocytes or Null Lymphocytes
- •2.1.1.2 Monocytes/Macrophages
- •Phagocytosis
- •Antigen-Presenting Cells
- •2.1.1.3 Polymorphonuclear Granulocytes
- •Neutrophils
- •Eosinophils
- •Basophils/Mast Cells
- •2.1.1.4 Platelets
- •2.1.2 Immunoregulation
- •2.1.2.1 Major Histocompatibility Complex
- •2.1.2.2 Humoral Mechanisms: Antibodies
- •2.1.2.3 Cellular Mechanisms
- •2.1.2.4 Summary
- •2.1.3 Abnormalities of the Immune Response
- •2.1.3.1 Hypersensitivity Reactions
- •Type III Hypersensitivity Reactions
- •Systemic Immune Complex Disease
- •Local Immune Complex Disease (Arthus Reaction)
- •Type IV Hypersensitivity Reactions
- •2.1.3.2 Autoimmunity
- •Mechanisms of Autoimmunity
- •2.2 Connective Tissue and the Immune Response
- •2.2.1 Fibroblast Functions and the Immune Response
- •2.3 The Sclera and the Immune Response: Scleritis
- •2.3.1 Immune Characteristics of the Sclera
- •2.3.2 The Susceptible Host: Immunogenetics
- •2.3.3 Etiology
- •2.3.3.1 Exogenous Agents
- •Viruses
- •Mycobacteria
- •2.3.3.2 Endogenous Substances
- •Glycosaminoglycans
- •Collagen
- •2.3.4 Pathogenesis
- •2.4 Summary
- •References
- •3.1 Investigation of the Illness
- •3.1.1 Major Complaint and History of Present Illness
- •3.1.2 Past History
- •3.1.3 Family History
- •3.1.4 Past and Present Therapy History
- •3.1.5 Review of Systems
- •3.1.6 Systemic Examination
- •3.1.6.1 Head
- •3.1.6.2 Extremities
- •3.1.7 Ocular Examination
- •3.1.7.1 Episcleral and Scleral Examination
- •External Examination of the Eye in Daylight
- •Slit-Lamp Examination
- •Diffuse Illumination
- •Slit-Lamp Illumination
- •Red-Free Illumination
- •3.1.7.2 General Eye Examination
- •Visual Acuity
- •Pupils and Extraocular Muscles
- •Cornea
- •Anterior Uvea
- •Lens
- •Fundus
- •Intraocular Pressure
- •3.2 Diagnostic Tests
- •3.2.1 Blood Tests
- •3.2.1.1 Rheumatoid Factor
- •3.2.1.2 Anticyclic Citrullinated Peptide Antibodies
- •3.2.1.3 Antinuclear Antibodies
- •3.2.1.4 Antineutrophil Cytoplasmic Antibodies
- •3.2.1.5 Circulating Immune Complexes
- •Fluid-Phase Binding Assays
- •C1q-Binding Assay
- •Cell-Binding Assays
- •Raji Cell-Binding Assay
- •3.2.1.6 Complement
- •Quantitation Tests
- •Functional Tests
- •3.2.1.7 HLA Typing
- •3.2.1.8 Antibody Titers Against Infectious Organisms
- •3.2.1.9 Interferon-Gamma Release Assays (IGRAs)
- •3.2.2 Anterior Chamber Polymerase Chain Reaction Testing
- •3.2.3 Smears and Cultures
- •3.2.4 Skin Testing
- •3.2.5 Radiologic Studies
- •3.2.6.1 Anterior Segment Fluorescein Angiography Techniques
- •3.2.6.2 Normal Anterior Segment Fluorescein Angiography
- •Arterial Phase
- •Capillary Phase
- •Venous Phase
- •3.2.7 Anterior Segment Indocyanine Green Angiography
- •3.2.8 Other Imaging Studies
- •3.2.8.1 Ultrasonography
- •A-Scan Ultrasonography
- •B-Scan Ultrasonography
- •High-Frequency Ultrasound Biomicroscopy
- •3.2.8.2 Optical Coherence Tomography
- •3.2.8.3 Computer Tomography Scanning
- •3.2.8.4 Magnetic Resonance Imaging
- •3.3 Biopsy
- •3.3.1 Biopsy for Suspected Systemic Vasculitic Disease
- •3.4 Data Integration: Diagnosis
- •3.5 Therapeutic Plan
- •3.6 Summary
- •References
- •4.1 Episcleritis
- •4.1.1 Introduction
- •4.1.2 Patient Characteristics
- •4.1.3 Clinical Manifestations
- •4.1.4.1 Simple Episcleritis
- •4.1.4.2 Nodular Episcleritis
- •4.1.5 Associated Diseases
- •4.1.6 Precipitating Factors
- •4.2 Scleritis
- •4.2.1 Introduction
- •4.2.2 Patient Characteristics
- •4.2.3 Clinical Manifestations
- •4.2.4.1 Diffuse Anterior Scleritis
- •4.2.4.2 Nodular Anterior Scleritis
- •Differential Diagnosis
- •Paralimbic Scleromalacia
- •Senile Scleral Hyaline Plaques
- •4.2.4.5 Posterior Scleritis
- •Symptoms and Signs
- •Fundus Findings
- •Choroidal Folds
- •Subretinal Mass
- •Disk Edema and Macular Edema
- •Annular Ciliochoroidal Detachment and Serous Retinal Detachment
- •Associated Diseases
- •Complications
- •Ancillary Tests
- •Ultrasonography
- •Computerized Tomography (CT) Scanning
- •Fluorescein Angiography
- •Differential Diagnosis
- •Proptosis, Chemosis, Lid Swelling, and Limitation of Ocular Movements
- •Subretinal Mass
- •Choroidal Folds
- •Annular Ciliochoroidal Detachment and/or Serous Retinal Detachment
- •Disk and Macular Edema
- •4.2.5 Associated Diseases
- •4.2.6 Complications of Scleritis
- •4.2.6.1 Keratopathy
- •Peripheral Corneal Thinning
- •Stromal Keratitis
- •Peripheral Ulcerative Keratitis
- •4.2.6.2 Uveitis
- •4.2.6.3 Glaucoma
- •Angle-Closure Glaucoma
- •Open-Angle Glaucoma
- •Neovascular Glaucoma
- •4.2.6.4 Cataract
- •4.3 Summary
- •References
- •5: Pathology in Scleritis
- •5.1.3 Fibrinoid Necrosis
- •5.2.1 Pathology of Episcleritis
- •5.2.2 Pathology of Scleritis
- •5.2.2.1 Noninfectious Scleritis
- •Sclera
- •Cells
- •Extracellular Matrix
- •Vessels
- •Episclera
- •Conjunctiva
- •Iris, Ciliary Body, and Choroid
- •Cornea
- •Other Ocular Structures
- •Polyarteritis Nodosa
- •Allergic Granulomatous Angiitis (Churg–Strauss Syndrome)
- •Granulomatosis with Polyangiitis (Wegener)
- •Connective Tissue Diseases
- •Clinicopathological Correlates in Infectious Scleritis
- •Systemic Infections
- •Local Infections
- •5.3 Biopsy
- •5.3.1 Noninfectious Necrotizing Scleritis
- •5.3.2 Noninfectious Recurrent Diffuse or Nodular (Nonnecrotizing) Scleritis
- •5.3.3 Infectious Scleritis (Diffuse, Nodular, or Necrotizing Scleritis)
- •5.3.4 Biopsy Technique
- •5.4 Summary
- •References
- •6: Noninfectious Scleritis
- •6.1.1 Adult Rheumatoid Arthritis
- •6.1.1.1 Epidemiology
- •Signs and Symptoms of Joint Involvement
- •Extraarticular Systemic Manifestations
- •6.1.1.2 Systemic Manifestations
- •Onset
- •Tegument
- •Vessels
- •Lung
- •Heart
- •Nervous System
- •Lymph Nodes
- •Larynx
- •Felty’s Syndrome
- •Amyloidosis
- •Miscellaneous
- •6.1.1.3 Ocular Manifestations
- •Keratoconjunctivitis Sicca
- •Scleritis
- •Keratitis
- •Anterior Uveitis
- •Glaucoma
- •Cataract
- •Retinal, Choroidal, and Optic Nerve Changes
- •Motility Disturbances
- •Episcleritis
- •6.1.1.4 Laboratory Findings
- •Rheumatoid Factor
- •Antibodies to Cyclic Citrullinated Polypeptides
- •Complete Blood Count
- •Acute-Phase Reactants
- •Synovial Fluid Analysis
- •Circulating Immune Complexes
- •Antinuclear Antibodies
- •Complement
- •Cryoglobulins
- •Radiographic Evaluation
- •Diagnosis
- •6.1.2 Systemic Lupus Erythematosus
- •6.1.2.1 Epidemiology
- •6.1.2.2 Systemic Manifestations
- •Musculoskeletal
- •Tegument
- •Vessels
- •Kidney
- •Hearth
- •Nervous System
- •Lung
- •Miscellaneous
- •6.1.2.3 Ocular Involvement
- •Scleritis
- •Episcleritis
- •Other Ocular Findings
- •6.1.2.4 Laboratory Findings
- •6.1.2.5 Diagnosis
- •6.1.3 Ankylosing Spondylitis
- •6.1.3.1 Epidemiology
- •6.1.3.2 Systemic Manifestations
- •Articular Involvement
- •Extraarticular Systemic Manifestations
- •6.1.3.3 Ocular Manifestations
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •6.1.3.5 Diagnosis
- •6.1.4 Reactive Arthritis (Reiter)
- •6.1.4.1 Epidemiology
- •6.1.4.2 Systemic Manifestations
- •Articular Involvement
- •Extraarticular Systemic Manifestations
- •6.1.4.3 Ocular Manifestations
- •Conjunctivitis
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •Other Ocular Findings
- •6.1.4.4 Laboratory and Radiographic Findings
- •6.1.4.5 Diagnosis
- •6.1.5 Psoriatic Arthritis
- •6.1.5.1 Epidemiology
- •6.1.5.2 Systemic Manifestations
- •Skin and Articular Involvement
- •6.1.5.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.5.4 Laboratory and Radiographic Findings
- •6.1.5.5 Diagnosis
- •6.1.6.1 Epidemiology
- •6.1.6.2 Systemic Manifestations
- •Gastrointestinal and Articular Manifestations
- •6.1.6.3 Ocular Manifestations
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •Keratitis
- •6.1.6.4 Laboratory and Joint Radiologic Findings
- •6.1.6.5 Diagnosis
- •6.1.7 Relapsing Polychondritis
- •6.1.7.1 Epidemiology
- •6.1.7.2 Systemic Manifestations
- •6.1.7.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.7.4 Laboratory Findings
- •6.1.7.5 Diagnosis
- •6.1.8 Polyarteritis Nodosa
- •6.1.8.1 Epidemiology
- •6.1.8.2 Systemic Manifestations
- •6.1.8.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.8.4 Laboratory and Angiographic Findings
- •6.1.8.5 Diagnosis
- •6.1.9.1 Epidemiology
- •6.1.9.2 Systemic Manifestations
- •6.1.9.3 Ocular Manifestations
- •6.1.9.4 Laboratory Findings
- •6.1.9.5 Diagnosis
- •6.1.10 Granulomatosis with Polyangiitis (Wegener)
- •6.1.10.1 Epidemiology
- •6.1.10.2 Clinical Manifestations
- •6.1.10.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.10.4 Laboratory Findings
- •6.1.10.5 Diagnosis
- •6.1.11 Adamantiades–Behçet’s Disease
- •6.1.11.1 Epidemiology
- •6.1.11.2 Systemic Manifestations
- •6.1.11.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.11.4 Laboratory Findings
- •6.1.11.5 Diagnosis
- •6.1.12 Giant-Cell Arteritis
- •6.1.12.1 Epidemiology
- •6.1.12.2 Systemic Manifestations
- •6.1.12.3 Ocular Manifestations
- •Scleritis
- •6.1.12.4 Laboratory Findings
- •6.1.12.5 Diagnosis
- •6.1.13 Cogan’s Syndrome
- •6.1.13.1 Clinical Manifestations
- •Scleritis
- •Episcleritis
- •6.1.13.2 Laboratory Findings
- •6.2.1 Rosacea
- •6.3.1 Gout
- •6.5 Chemical Injury-Associated Scleritis
- •6.6 Summary
- •References
- •7: Infectious Scleritis
- •7.1 Bacterial Scleritis
- •7.1.1.1 Pathogenesis
- •7.1.1.2 Organisms
- •7.1.1.3 Management
- •7.1.1.4 Therapy
- •7.1.1.5 Prognosis
- •7.1.1.6 Our Experience
- •7.1.2 Mycobacterial Scleritis
- •7.1.2.1 Atypical Mycobacterial Disease
- •7.1.2.2 Tuberculosis
- •7.1.2.3 Leprosy
- •7.1.3 Spirochetal Scleritis
- •7.1.3.1 Syphilis
- •Epidemiology
- •Pathogenesis and Clinical Features
- •Scleritis and Episcleritis
- •Diagnosis
- •Therapy
- •7.1.3.2 Lyme Disease
- •Epidemiology
- •Pathogenesis and Clinical Features
- •Scleritis and Episcleritis
- •Diagnosis
- •7.1.3.3 Treatment
- •7.1.4 Chlamydial Scleritis
- •7.1.5 Actinomycetic Scleritis
- •7.1.5.1 Nocardiosis
- •7.2 Fungal Scleritis
- •7.2.1 Filamentous and Dimorphic Fungal Scleritis
- •7.2.1.1 Pathogenesis
- •7.2.1.2 Organisms
- •7.2.1.3 Management
- •7.2.1.4 Therapy
- •7.2.1.5 Our Experience
- •7.3 Viral Scleritis
- •7.3.1 Herpes Scleritis
- •7.3.1.1 Herpes Zoster Scleritis
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Scleritis
- •Episcleritis
- •Diagnosis
- •Treatment
- •7.3.1.2 Herpes Simplex Scleritis
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Scleritis
- •Episcleritis
- •Diagnosis
- •Therapy
- •Our Experience
- •7.3.2 Mumps Scleritis
- •7.4 Parasitic Scleritis
- •7.4.1 Protozoal Scleritis
- •7.4.1.1 Acanthamoeba
- •7.4.1.2 Toxoplasmosis
- •7.4.2 Helminthic Scleritis
- •7.4.2.1 Toxocariasis
- •7.5 Summary
- •References
- •8.1 Scleral Deposits
- •8.1.1 Scleral Protein Deposition
- •8.1.1.1 Porphyria
- •8.1.1.2 Cystinosis
- •8.1.1.3 Alkaptonuria
- •8.1.1.4 Amyloidosis
- •8.1.2 Scleral Lipid Deposition
- •8.1.2.1 Familial Hypercholesterolemia and Histiocytosis X
- •8.1.2.2 Age-Related Degeneration
- •8.1.3 Scleral Carbohydrate Deposition
- •8.1.3.1 Mucopolysaccharidosis
- •8.1.4 Scleral Mineral Deposition: Calcium
- •8.1.4.1 Hyperparathyroidism
- •8.1.4.2 Other Causes of Hypercalcemia
- •8.1.4.3 Age-Related Degeneration
- •Senile Scleral Hyaline Plaques
- •8.1.5 Scleral Pigment Deposition: Bilirubin
- •8.1.5.1 Jaundice
- •8.2 Scleral Thinning (Blue Sclerae)
- •8.2.1 Scleral Thinning in Inherited or Congenital Diseases
- •8.2.1.1 Marfan’s Syndrome
- •8.2.1.2 Osteogenesis Imperfecta
- •8.2.1.3 Pseudoxanthoma Elasticum
- •8.2.1.4 Ehlers–Danlos Syndrome
- •8.2.1.5 Keratoconus
- •8.2.1.6 Buphthalmos
- •8.2.1.7 Coloboma
- •8.2.1.8 Myopia
- •8.2.2 Scleral Thinning in Acquired Diseases
- •8.2.2.2 Paralimbal Scleromalacia
- •8.3 Scleral Thickening
- •8.3.1 Nanophthalmos
- •8.3.2 Scleropachynsis
- •8.3.3 Phthisis Bulbi
- •8.4 Scleral Tumors
- •8.4.1 Dermoid Choristomas
- •8.4.2 Epithelial Tumors
- •8.4.2.1 Papillomas or Intraepithelial Epitheliomas
- •8.4.2.2 Squamous Cell Carcinoma
- •8.4.3 Dense Connective Tissue Tumors
- •8.4.3.1 Nodular Fasciitis
- •8.4.3.2 Fibroma
- •8.4.3.3 Fibrous Histiocytoma
- •8.4.3.4 Sarcomas
- •8.4.4 Vascular Tumors
- •8.4.4.1 Hemangiomas
- •8.4.4.2 Lymphangiomas
- •8.4.5 Blood Cell Tumors
- •8.4.5.1 Leukemia
- •8.4.5.2 Lymphoma and Lymphosarcoma
- •8.4.6 Nervous Tumors
- •8.4.6.2 Neurilemmoma (Schwannoma)
- •8.4.7 Pigmented Tumors
- •8.4.7.1 Nevus
- •8.4.7.2 Melanocytoma
- •8.4.8 Secondary Tumors
- •8.5 Summary
- •References
- •9.1 Treatment of Episcleritis
- •9.2 Treatment of Scleritis
- •9.2.1 Medical Treatment
- •9.2.1.1 Rheumatoid Arthritis
- •9.2.1.2 Systemic Lupus Erythematosus
- •9.2.1.3 Polyarteritis Nodosa
- •9.2.1.4 Granulomatosis with Polyangiitis (Wegener)
- •9.2.1.5 Relapsing Polychondritis
- •9.2.1.7 Posterior Scleritis
- •9.2.1.8 Infectious Scleritis
- •9.2.2 Ancillary Therapy
- •9.2.3 Drug Management Responsibility
- •9.2.4 Surgical Treatment
- •9.3 Summary
- •References
- •Index
1.7 Molecular Structure |
23 |
|
|
absent in extravascular sclera but was dramatically represented in vessel walls.
Scleral blood vessels showed the presence of collagen types IV, V, and VI, the GAGs heparan sulfate and chondroitin sulfate, and the glycoproteins Þbronectin and laminin in endothelial cell basement membranes.
1.6Biomechanics
By virtue of its poor distensibility, the sclera provides a stable viscoelastic system for the globe. This property appears to be dependent, at least in part, on the GAG water-binding properties: the higher the water-holding capacity of the GAG, the more distensible the sclera. The adult sclera exhibits a biphasic response to a sudden force: a rapid lengthening is followed by a slow stretching [62Ð64]. However, like most viscoelastic systems, the sclera stretches proportionately more with small pressure changes. The sclera stretches with initial elevations of intraocular pressure; therefore, small increases in intraocular volume at low pressure result in small increases in intraocular pressure. As the pressure increases, the resistance to further stretching also increases, and therefore small increases in intraocular volume at high pressures result in large increases in intraocular pressure. Following severe transient stretching of the sclera, as in acute glaucoma, scleral distensibility returns to the baseline levels prior to the increase of intraocular pressure.
Scleral distensibility is an important consideration when methods of intraocular pressure measurement are studied. The indentation method results in a signiÞcant increase of intraocular volume; the applanation method does not. In some eyes with increased scleral distensibility (e.g., as produced by inßammatory diseases, high myopia, or retinal detachment surgery), the indentation measurement method results in a false low reading because the sclera stretches to accommodate the pressure of the tonometer.
Scleral distensibility decreases with age [65]. This property appears to depend, at least in part, on the degree of hydration of connective tissue; highly hydrated tissues, such as embryonic skin
or fetal cornea, are highly distensible, whereas adult tissues become more rigid as their waterholding capacity decreases [66Ð69]. Posterior sclera is more distensible than anterior sclera, and the choroid is more distensible than the sclera; the latter helps explains why the choroid forms redundant folds in orbital or choroidal tumors, ocular hypotony, and subretinal neovascularization.
1.7Molecular Structure
Scleral connective tissue consists of cells and extracellular matrix. The cells, or Þbroblasts, play a critical role in the synthesis and organization of the matrix elements. The extracellular matrix is composed of Þbrillar proteins, such as collagen and elastin, and of amorphous ground substance, such as proteoglycans and glycoproteins. The speciÞc turnover rate of the scleral matrix by Þbroblasts and the degradative enzymes they secrete (collagenases, elastases, proteoglycanases, and glycoproteinases) is unknown, but collagen Þbrils have a slower turnover rate than proteoglycans [70]. Healing of scleral wounds, based on a delicate balance of Þbroblast matrix synthesis and enzyme matrix degradation, is a slow process, taking months or years, and the area of the wound can always be identiÞed histologically by the abrupt change in scleral collagen Þber orientation and disorganization that persists throughout the life of the individual [71].
1.7.1Collagen
Collagen types I, III, IV, V, VI, and VIII have been identiÞed in scleral tissue. Each collagen molecule is composed of three polypeptide a chains containing triple-helical and globular domain [72, 73]. The triple-helical regions have a repeating triplet amino acid sequence, summarized as (Gly- X-Y)n, where X and Y are often proline and hydroxyproline, respectively. The presence of glycine at every third residue, with the exception of short sequences at the ends of the chain, contributes to the triple-helical conformation.
24 |
1 Structural Considerations of the Sclera |
|
|
Interchain hydrogen bonds, especially with the hydroxyl groups of hydroxyproline, stabilize the triple-helical structure.
Collagen biosynthesis by scleral Þbroblasts is a complex process consisting of several speciÞc intracellular steps. Each polypeptide pro-a chain is a distinct gene product [74Ð76]. The pro-a chains, assembled in the lumen of the rough endoplasmic reticulum, undergo hydroxylation of speciÞc proline and lysine residues by the action of prolyl-3-hydroxylase, prolyl-4-hydrox- ylase, and lysyl hydroxylase. Subsequent to hydroxylation, some of the hydroxylysine residues become glycosylated by the action of glycosyltransferases. After completion of the synthesis, the pro-a chain has two globular domains, the NH2 terminal and the COOH terminal. Following alignment of three polypeptide pro-a chains, interchain and intrachain disulÞde bonds form at the COOH-terminal propeptides, stabilizing and facilitating helix formation. Procollagen type I contains interchain disulÞde bonds within the COOH-terminal propeptides. Procollagen type III contains interchain disulÞde bonds within the NH2-terminal propeptides as well. DisulÞde bonds within the NH2-terminal propeptides form after helix formation [77]. The assembled triplehelical procollagen type I and III molecules are secreted into the extracellular space, where the terminal propeptides are proteolytically removed. The resulting molecules have a remarkable tendency for spontaneous formation of Þbrils [78].
1.7.2Elastin
Small but important amounts of the Þbrillar protein elastin are synthesized by scleral Þbroblasts as part of the extracellular matrix. Elastin is composed primarily of nonpolar hydrophobic amino acids, such as alanine, valine, isoleucine, and leucine, and contains little hydroxyproline and no hydroxylysine [79]. It also contains two unique amino acids, desmosine and isodesmosine, which serve to cross-link the polypeptide chains. Studies on genomic elastin clones from chick embryo aortas indicate that the rate of elastin synthesis is controlled at the level of transcription [73].
1.7.3Proteoglycans
Proteoglycans are complex molecules, synthesized by scleral Þbroblasts and consisting of a core protein of varying length to which GAG chains are covalently linked. GAGs are longchain, unbranched, linear polymers of repeating disaccharide units. One constituent of the unit is an N-acetylated amino sugar, which may or may not be sulfated, and the other is a uronic acid. The high-molecular-weight proteoglycan molecule is composed of 1 or 2 to more than 100 GAG chains with a potential of giving more than 10,000 negatively charged groups per proteoglycan molecule [80, 81]. During synthesis, assembly of the protein core and initiation of the GAG chain occur together in the rough endoplasmic reticulum. One or two different types of GAG chains attach to the core protein at one end and radiate from it in a bottle-brush conÞguration [80].
At least four types of GAGs have been detected in scleral tissue [61]. Dermatan sulfate, chondroitin sulfate, heparan sulfate, and hyaluronic acid largely compose the amorphous ground substance present in the intercellular and interÞbrillar spaces of the sclera. Dermatan sulfate consists of sulfated N-acetylgalactosamine and two different types of uronic acid, glucuronic acid and iduronic acid; chondroitin sulfate consists of sulfated N-acetylgalactosamine and glucuronic acid; heparan sulfate consists of sulfated N-acetylglucosamine and two different types of uronic acid, glucuronic acid and iduronic acid; hyaluronic acid consists of N-acetylglucosamine and glucuronic acid (it is not linked to a core protein and lacks a sulfate group).
Proteoglycans interact with collagen, determining the organization and size of collagen Þbrils [82Ð85]. They also interact with glycoproteins, such as Þbronectin. Most of these interactions are mediated by the GAG component, although some are mediated by the core protein of proteoglycan [86, 87]. The decrease in collagen Þbril arrangement and increase in collagen Þbril size in the area of transition from cornea to sclera coincide with the disappearance of keratan sulfate and the appearance of highly sulfated galactosaminoglycans, such as dermatan sulfate
1.7 Molecular Structure |
25 |
|
|
and chondroitin sulfate [60]. Proteoglycans maintain the proper anatomical structure of the collagen Þbrils and protect them from attack [70]. Proteoglycans also function as modulators of growth factors, such as Þbroblast growth factor or transforming growth factor [82].
1.7.4Glycoproteins
Although collagen, elastin, and proteoglycans are technically glycosylated proteins, the term glycoprotein is primarily used for molecules composed of oligosaccharide with a mannose core N-glycosidically linked to asparagine. The glycoprotein Þbronectin has been detected in sclera as part of the amorphous ground substance [58].
Fibronectin is a high-molecular-weight molecule synthesized by scleral Þbroblasts. It consists of two similar subunits joined near their COOH termini by disulÞde bonds [88]. Each subunit can be divided into a number of globular domains that have speciÞc binding characteristics. There are binding sites for Þbrin, heparin, bacteria, collagen, DNA, cell membranes, and a variety of other macromolecules. Fibronectin is thought to be important in the organization of the pericellular and intercellular matrix by its ability to bind to collagen, Þbroblasts, and GAGs [89, 90]. Antibodies directed against the collagen-binding domain of Þbronectin have been shown to inhibit collagen Þbril deposition [91]. Fibronectin has also been found to play a role in host defense, presumably by its ability to interact with C1q component of complement, Þbrin, bacteria, and DNA [92Ð94]. Characterization of Þbronectin cDNA clones indicates that only a single Þbronectin gene exists; but multiple forms of cellular Þbronectin are generated by alternative splicing of mRNA [95Ð97]. These alternatively spliced forms appear to have differential functions in embryogenesis, defense, wound healing, and homeostatic cell maintenance.
Laminin, a glycoprotein found in basement membranes, consists of three polypeptide chainsÑA(440 kDa), and B1 and B2 (each 220 kDa)Ñlinked via disulÞde bonds to form an asymmetric cross-structure [98]. Laminin
possesses multiple functional sites that mediate its interactions with cells, such as endothelial cells, and with other extracellular matrix components, such as GAGs, nonintegrin proteins, and integrins [99]. Cells and extracellular matrix proteins interact with laminin via speciÞc surface receptors. Laminin participates in the promotion of cell adhesion, growth, migration, and differentiation, as well as assembly of basement membranes [100].
The fact that laminin is the Þrst extracellular matrix protein to appear in development emphasizes its importance in the intricate process of tissue organization [98].
1.7.5Matrix-Degrading Enzymes
Collagenase, elastase, proteoglycanase, and glycoproteinase are enzymes capable of degrading the matrix components. Some of these enzymes are synthesized by the scleral Þbroblasts themselves, whereas others are secreted by inßammatory cells, such as neutrophils and macrophages.
Collagenase degrades cross-linked type I and type II collagen Þbrils by attacking the collagen molecule at one speciÞc locus one-quarter of the distance from the COOH-terminal. Two fragments, TCA and TCB, three-quarters and onequarter of the collagen molecule, respectively, are generated. These fragments denature spontaneously at temperatures greater than 33¡C, are phagocytosed, and become susceptible of further attack in the lysosomes by proteinases, such as cathepsins B and N. Collagen degradation in normal and inßamed tissues depends on the balance between the collagenase and its inhibitors [101]. The protein core of the proteoglycans must be broken by proteoglycanases for the collagenase to come into contact with the underlying collagen [70].
Elastase is a powerful proteinase that, unlike collagenase, lacks speciÞcity. It degrades not only elastin, but also other components of the extracellular matrix, such as collagen and proteoglycans. The neutrophil and macrophage elastases may be important in degrading elastin in inßammatory reactions [102].
